| Title | | | Author(s) | Ye M, Bhat G, Johnston KA, Tan H, Garnick M | | Institution | 1Associate Director of Pharmaceutics and Drug Delivery Technology, Praecis Pharmaceuticals Inc., 830 Winter Street, Waltham, MA 02451, USA. mingye02@hotmail.com , 2Director of Biometrics, Praecis Pharmaceuticals Inc., 830 Winter Street, Waltham, MA 02451, USA, 3Associate Director of Pharmaceutical Development and Analytical Technology, Praecis Pharmaceuticals Inc., 830 Winter Street, Waltham, MA 02451, USA, 4Vice President of Development and Industrial Operations, Praecis Pharmaceuticals Inc., 830 Winter Street, Waltham, MA 02451, USA, 5Chief Medical Officer, Praecis Pharmaceuticals Inc., 830 Winter Street, Waltham, MA 02451, USA. | | Source | Expert Opin Drug Deliv 2006 Sep; 3(5):663-675. | | Abstract | Proprietary Rel-Easetrade mark (Praecis Pharmaceuticals) drug delivery technology uses biocompatible polymers as carriers to incorporate a drug into a polymer matrix through opposite charge interaction or complexation. The resulting low solubility complexes can be used to prepare sustained release depot injections or potentially sustained release formulations for oral administration. As a regulatory approved and commercialised drug delivery technology, Rel-Ease is used in abarelix for injectable suspension, a monthly depot injection for the treatment of patients with advanced prostate cancer. The technology offers high drug loading and minimal-to-no initial burst effect in vivo. It uses aqueous processes and is compatible for complexation with many peptide and protein therapeutics; its mechanism can also be applied to many small-molecule therapeutics and offers conventional and alternative methods for sustained release delivery via an oral route. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 16948561 |
|
